Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: Implications for Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 5, 2015, Pages 1780-1791

  Turano, Ermanna ^a   Busetto, Giuseppe ^a,b   Marconi, Silvia ^a   Guzzo, Flavia ^a   Farinazzo, Alessia ^a   Commisso, Mauro ^a   Bistaffa, Edoardo ^a   Angiari, Stefano ^a   Musumeci, Salvatore ^c   Sotgiu, Stefano ^d   Bonetti, Bruno ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Italian Institute of Neuroscience   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Alzheimer's disease; Amyloid; LTP; N acetylglucosamine; Neurotoxicity

Indexed keywords

CHITIN; N ACETYLGLUCOSAMINE; POLYMER; SYNAPTOPHYSIN; SYNTAXIN; URIDINE DIPHOSPHATE;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; LONG TERM POTENTIATION; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ACETYLGLUCOSAMINE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; CELLS, CULTURED; FEMALE; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; MICE; MICROGLIA; MIDDLE AGED; NEURONAL PLASTICITY; NEURONS; POLYMERS; QA-SNARE PROTEINS; SYNAPTOPHYSIN;

EID: 84933180002     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.12.033     Document Type: Article

References (63)

1. Abbott A. The plaque plane. Nature 2008, 456:161-164.
2. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol 2004, 61:661-666.
3. Bakkers J., Semino C.E., Stroband H., Kijne J.W., Robbins P.W., Spaink H.P. An important developmental role for oligosaccharides during early embryogenesis of cyprinid fish. Proc. Natl. Acad. Sci. U.S.A 1997, 94:7982-7986.
4. Barone R., Sotgiu S., Musumeci S. Plasma chitotriosidase in health and pathology. Clin. Lab 2007, 53:321-333.
5. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., McInnis M.G., Go R.C., Vekrellis K., Selkoe D.J., Saunders A.J., Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000, 290:2302-2303.
6. Boot R.G., Renkema G.H., Verhoek M., Strijland A., Bliek J., de Meulemeester T.M., Mannens M.M., Aerts J.M. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J. Biol. Chem 1998, 273:25680-25685.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complication. Nature 2001, 414:813-820.
8. Brureau A., Zussy C., Delair B., Ogier C., Ixart G., Maurice T., Givalois L. Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer's disease rat model. Neurobiol. Aging 2013, 34:1426-1439.
9. Castellani R.J., Siedlak S.L., Fortino A.E., Perry G., Ghetti B., Smith M.A. Chitin-like polysaccharides in Alzheimer's disease brains. Curr. Alzheimer Res 2005, 2:419-423.
10. Castellani R.J., Perry G., Smith M.A. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res 2007, 12:269-274.
11. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci 1999, 2:271-276.
12. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides. J. Neurosci. Res 2000, 60:65-72.
13. Da Silva C.A., Hartl D., Liu W., Lee C.G., Elias J.A. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J. Immunol 2008, 181:4279-4286.
14. Do T.D., Economou N.J., Chamas A., Buratto S.K., Shea J.E., Bowers M.T. Interactions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J. Phys. Chem. B 2014, 118:11220-11230.
15. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., Siemers E., Liu-Seifert H., Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med 2014, 370:311-321. Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.
16. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
17. Games D., Adam D., Alessandrini R., Barbour R., Berthelette P., Blakwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
18. Glaser L., Brown D.H. The synthesis of chitin in cell-free extracts of Neurospora crassa. J. Biol. Chem 1957, 228:729-742.
19. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol 2007, 8:101-112.
20. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo controlled phase I trial. Lancet 2008, 372:216-223.
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
22. Ishii K., Kitagaki M., Kono M., Mori E. Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. J. Nucl. Med 1996, 37:1159-1165.
23. Ishii K., Inamura T., Sasaki M., Yamaji S., Sakamoto S., Kitagaki H., Hashimoto M., Hirono N., Shimomura T., Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998, 51:125-130.
24. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wölfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Götz J. Dendritic function of tau mediates amyloid toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
25. Koffie M.R., Hyman B.T., Spires-Jones T.L. Alzheimer's disease: synapses gone cold. Mol. Neurodegener 2011, 6:63.
26. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A 1998, 95:6448-6453.
27. Lee C.G., Da Silva C.A., Lee J.Y., Hartl D., Elias J.A. Chitin regulation of immune responses: an old molecule with new roles. Curr. Opin. Immunol 2008, 20:684-689.
28. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol 2010, 6:108-119.
29. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
30. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
31. Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci 2011, 31:6627-6638.
32. Love D.C., Hanover J.A. The hexosamine signaling pathway: deciphering the O-GlcNAc code. Sci. STKE 2005, 13:654-662.
33. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
34. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med 1995, 36:1238-1248.
35. Muzzarelli R.A. Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell Mol. Life Sci 1997, 53:131-140.
36. Nishimura K., Nishimura S., Nishi N., Saiki I., Tokura S., Azuma I. Immunological activity of chitin and its derivatives. Vaccine 1984, 2:93-99.
37. Nomura I., Kato N., Kita T., Takechi H. Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci. Lett 2005, 391:1-6.
38. Nowotny P., Hinrichs A.L., Smemo S., Kauwe J.S., Maxwell T., Holmans P., Hamshere M., Turic D., Jehu L., Hollingworth P., Moore P., Bryden L., Myers A., Doil L.M., Tacey K.M., Gibson A.M., McKeith I.G., Perry R.H., Morris C.M., Thal L., Morris J.C., O'Donovan M.C., Lovestone S., Grupe A., Hardy J., Owen M.J., Williams J., Goate A. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am. J. Med. Genet. B Neuropsychiatr. Genet 2005, 136:62-68.
39. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci 2006, 26:10129-10140.
40. O'Callaghan P., Sandwall E., Li J.P., Yu H., Ravid R., Guan Z.Z., van Kuppevelt T.H., Nilsson L.N., Ingelsson M., Hyman B.T., Kalimo H., Lindahl U., Lannfelt L., Zhang X. Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol 2008, 18:548-561.
41. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., La Ferla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
42. Piert M., Koeppe R.A., Giordani B., Berent S., Kuhl D.E. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J. Nucl. Med 1996, 37:201-208.
43. Piras I., Melis A., Ghiani M.E., Falchi A., Luiselli D., Moral P., Varesi L., Calò C.M., Vona G. Human CHIT1 gene distribution: new data from Mediterranean and European populations. J. Hum. Genet 2007, 52:110-116.
44. Querfurth H.W., La Ferla F.M. Alzheimer's Disease. N. Engl. J. Med 2010, 362:329-344.
45. Raymond C.R., Ireland D.R., Abraham W.C. NMDA receptor regulation by amyloid-β does not account for its inhibition of LTP in rat hippocampus. Brain Res 2003, 968:263-272.
46. Salloway S., Sperilng R., Fox N.C., Blennow K., Klunk W., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., Ferris S., Reichert M., Ketter N., Nejadnik B., Guenzler V., Miloslavsky M., Wang D., Lu Y., Lull J., Tudor I.C., Liu E., Grundman M., Yuen E., Black R., Brashear H.R. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med 2014, 370:322-333. Bapineuzumab 301 and 302 Clinical Trial Investigators.
47. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behaviour. Behav. Brain Res 2008, 192:106-113.
48. Semino C.E., Specht C.A., Raimondi A., Robbins P.W. Homologs of the Xenopus developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod-like chitin oligosaccharides during early embryogenesis. Proc. Natl. Acad. Sci. U.S.A 1996, 93:4548-4553.
49. Shah K., DeSilva S., Abbruscato T. The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer's Disease. Int. J. Mol. Sci 2012, 13:12629-12655.
50. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzeimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci 2007, 27:2866-2875.
51. Shankar G.M., Metha T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
52. Shibata Y., Metzger W.J., Myrvik Q.N. Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol 1997, 159:2462-2467.
53. Simpson I.A., Chundu K.R., Davies-Hill T., Honer W.G., Davies P. Decreased concentration of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol 1994, 35:546-551.
54. Simpson I.A., Davies P. Reduced glucose transporter concentrations in brains of patients with Alzheimer's disease. Ann. Neurol 1994, 36:800-801.
55. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-β. Nature Neurosci 2005, 8:1051-1058.
56. Sotgiu S., Piras M.R., Barone R., Arru G., Fois M.L., Rosati G., Musumeci S. Chitotriosidase and Alzheimer's disease. Curr. Alzheimer Res 2007, 4:295-296.
57. Sotgiu S., Musumeci S., Marconi S., Gini B., Bonetti B. Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains. J. Neuroimmunol 2008, 197:70-73.
58. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem 2003, 278:11612-11622.
59. Timmer N.M., Kuiperij H.B., de Waal R.M.W., Verbeek M.M. Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?. J. Alzheimer Dis 2010, 22:345-355.
60. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol 2006, 572:477-492.
61. Turner P.R., O'Connor K., Tate W.P., Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol 2003, 70:1-32.
62. Van Horssen J., Wesseling P., Van den Heuvel L.P., de Waal R.M., Verbeek M.M. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2003, 2:482-492.
63. Yoshida M., Itano N., Yamada Y., Kimata K. In vitro synthesis of hyaluronan by a single protein derived from mouse HAS1 gene and characterization of amino acid residues essential for the activity. J. Biol. Chem 2002, 275:497-506.